Regulatory Update

Vancouver – September 23, 2026 -- Silvercorp Metals Inc. (TSX/NYSE American: SVM) has postponed its annual general and special meeting from September 25 to October 2, 2026, after its Board approved a broadened package of Articles amendments beyond the Hong Kong Stock Exchange listing alignment originally proposed in the August 12 management circular. The proxy voting deadline has been pushed to September 30, 2026 at 10:00 a.m. Pacific time to give shareholders time to review the expanded resolution.

New York – September 23, 2026 -- Chainguard has been authorized by the CVE Program as a CVE Numbering Authority (CNA), granting it the power to assign official vulnerability identifiers for qualifying open source flaws surfaced through its Athena coalition.

Chainguard gains authority to assign CVE identifiers for unclaimed open source flaws

The CNA scope covers cases where upstream maintainers have already fixed a flaw without issuing an identifier, where no maintainer remains to assign one, or where no more specific CNA covers the affected project. Chainguard's CVE Records will defer to maintainers and project-specific CNAs wherever they exist.

Milwaukee – September 23, 2026 -- More than 90% of patients carrying a documented penicillin allergy in their electronic medical records can safely take the drug after clinical evaluation, according to the American Academy of Allergy, Asthma & Immunology (AAAAI), which is marking National Penicillin Allergy Day on September 28 with a push for wider adoption of allergy "de-labeling" protocols.

Inaccurate allergy labels block access to first-line infection treatment

Penicillin remains the most effective therapy for many bacterial infections, yet patients with unverified allergy labels are routinely steered toward alternative antibiotics. The AAAAI states that removing inaccurate labels through evaluation improves patient outcomes, lowers healthcare costs and supports efforts against antimicrobial resistance.

Trenton – September 23, 2026 -- New Jersey Gov. Mikie Sherrill has signed bipartisan legislation (A5016/S4218) creating an Employee Ownership Transition Program and a revolving loan fund at the New Jersey Economic Development Authority (NJEDA) to finance conversions of businesses into employee-owned firms.

NJEDA revives a financing model that returned ninefold on its original loan

The new Employee Ownership Revolving Loan Fund reactivates a mechanism NJEDA first used 50 years ago to finance the employee buyout of the Okonite Company in Passaic County. That original loan was fully repaid and revolved nine times over; Okonite remains 100% employee-owned today and has distributed more than $300 million in ESOP payouts to workers. The fund can draw capital from state appropriations, federal sources including U.S. Economic Development Administration grants, and philanthropic capital.

Ottawa – September 22, 2026 -- Nearly 60% of Ottawa's occupied private dwellings were built in 1990 or earlier, placing them squarely within the era when asbestos was commonly used in construction, according to a housing-age analysis published by PatchBoyz Asbestos Removal. Statistics Canada's 2021 Census counts 243,080 of Ottawa's 407,250 occupied private dwellings as built in 1990 or earlier, equal to 59.7%.

Charlottesville, Va. – September 22, 2026 -- RIVANNA has filed its 100th patent, U.S. application #64/080,862, covering an AI-powered ultrasound pathology detection pipeline for automated computer-aided diagnosis on its Accuro XV platform, marking 15 years of continuous intellectual-property development at the medical technology company.

Redmond – September 22, 2026 -- SystImmune Inc. has secured U.S. Food and Drug Administration clearance for its Investigational New Drug application for SI-B037, a bispecific antibody, marking the first time the company has built a regulatory submission entirely on New Approach Methodologies (NAMs) rather than traditional animal toxicology studies.

SystImmune replaces animal testing with human organ-on-chip models

The IND package for SI-B037 relied on human organ-on-chip systems and primary human tissue models instead of conventional animal studies to assess nonclinical safety. Dr. Jahan Khalili, Senior Vice President of Research at SystImmune, said the human-relevant models provided a more direct read on a molecule engineered to engage multiple human pathways simultaneously.

Toronto – September 22, 2026 -- The United States Patent and Trademark Office has allowed BiomeRenewables Inc.'s Application No. 18/942094, covering the serration structure behind its FeatherEdge® wind turbine blade technology, the Canadian cleantech firm announced.

Patent covers owl-inspired serration design that cuts turbine noise

The application, titled "STRUCTURE WITH SERRATIONS ADAPTED TO TRAVERSE A FLUID ENVIRONMENT," protects Biome's double-dip serration design modeled on the silent flight of owls. The technology reduces aerodynamic noise from wind turbine blades while increasing power output, according to the company.

Cleveland – September 22, 2026 -- Inglewood Associates and Gordon Brothers confirmed that the court-appointed Receiver overseeing the sale of 925 Euclid Avenue in Cleveland has not selected a stalking horse bidder, despite months of marketing the 1.45 million-square-foot historic tower.

Bidders opt for open auction over stalking horse role

Victor, Montana – – September 22, 2026 -- Ridgeway Pharmacy, Ltd. has confirmed that a vulnerability in its vendor-supported website allowed an unauthorized third party to gain elevated access, potentially exposing patient names, dates of birth, addresses, prescription and health information, insurance details, and, for some individuals, payment card data.

Ridgeway confirms breach originated in vendor-managed site, not internal systems

The pharmacy said the compromise was limited to its externally developed website and did not touch Ridgeway's own internal infrastructure. External cybersecurity and forensic specialists were brought in after operational irregularities were first detected on the site.